On November 6, 2023 NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used to detect and treat cancer, reported that it will participate in the upcoming 2023 Truist Securities Biopharma Symposium being held November 8 to 9, 2023, in New York, NY (Press release, NorthStar Medical Radiostopes, NOV 6, 2023, View Source [SID1234637084]). NorthStar executives Stephen Merrick, Executive Chairman, and Paul Estrem, Executive Vice President and Chief Financial Officer, will host one-on-one meetings with investors on November 8, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"NorthStar continues to expand our leadership position in the rapidly growing area of therapeutic radioisotopes, radiopharmaceuticals, and radiopharmaceutical contract development manufacturing organization (CDMO/CMO) services," said Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar Medical Radioisotopes. "We are routinely producing therapeutic copper-67 and poised to be one of the first commercial-scale producers of non-carrier added (n.c.a.) actinium-225. NorthStar is strongly positioned for continued rapid growth across the radiopharmaceutical sector, and we look forward to sharing information about our innovative and environmentally sustainable approach to radioisotope production with the investor community at this Truist Biopharma Symposium."